Stevanato Group (NYSE:STVN) Trading Down 3.6% – What’s Next?

Stevanato Group S.p.A. (NYSE:STVN)’s stock price was down 3.6% on Tuesday . The company traded as low as €21.28 ($22.88) and last traded at €21.54 ($23.16). Approximately 11,071 shares traded hands during trading, a decline of 97% from the average daily volume of 341,550 shares. The stock had previously closed at €22.35 ($24.03).

Wall Street Analysts Forecast Growth

STVN has been the topic of a number of recent research reports. Morgan Stanley restated an “equal weight” rating and issued a $23.00 target price (down previously from $24.00) on shares of Stevanato Group in a report on Tuesday, December 3rd. William Blair restated an “outperform” rating on shares of Stevanato Group in a research note on Friday, March 7th. Bank of America upped their target price on shares of Stevanato Group from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, December 13th. UBS Group dropped their price target on shares of Stevanato Group from $24.00 to $23.50 and set a “neutral” rating on the stock in a research report on Friday, March 7th. Finally, Wolfe Research began coverage on shares of Stevanato Group in a research note on Friday, December 13th. They issued an “outperform” rating and a $28.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Stevanato Group has a consensus rating of “Moderate Buy” and a consensus price target of €25.70 ($27.63).

Stevanato Group Stock Performance

The company has a market capitalization of $6.36 billion, a P/E ratio of 44.68, a P/E/G ratio of 7.18 and a beta of 0.60. The company has a current ratio of 1.81, a quick ratio of 1.21 and a debt-to-equity ratio of 0.22. The company’s fifty day moving average is €21.01 and its 200 day moving average is €20.59.

Stevanato Group (NYSE:STVN) last announced its quarterly earnings results on Thursday, March 6th. The company reported €0.20 ($0.22) earnings per share for the quarter, meeting the consensus estimate of €0.20 ($0.22). Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. The company had revenue of €352.68 million during the quarter, compared to analysts’ expectations of €346.26 million. As a group, equities analysts anticipate that Stevanato Group S.p.A. will post 0.5 earnings per share for the current year.

Hedge Funds Weigh In On Stevanato Group

Large investors have recently modified their holdings of the company. Hardy Reed LLC increased its stake in Stevanato Group by 8.2% in the 3rd quarter. Hardy Reed LLC now owns 11,077 shares of the company’s stock worth $222,000 after acquiring an additional 840 shares during the last quarter. First Bank & Trust grew its stake in Stevanato Group by 7.3% in the 4th quarter. First Bank & Trust now owns 15,145 shares of the company’s stock worth $330,000 after buying an additional 1,036 shares in the last quarter. Truist Financial Corp increased its holdings in shares of Stevanato Group by 4.2% in the 4th quarter. Truist Financial Corp now owns 26,900 shares of the company’s stock worth $586,000 after buying an additional 1,073 shares during the last quarter. Oppenheimer Asset Management Inc. increased its holdings in shares of Stevanato Group by 9.7% in the 4th quarter. Oppenheimer Asset Management Inc. now owns 12,874 shares of the company’s stock worth $281,000 after buying an additional 1,141 shares during the last quarter. Finally, US Bancorp DE raised its position in shares of Stevanato Group by 17.9% during the 4th quarter. US Bancorp DE now owns 8,527 shares of the company’s stock valued at $186,000 after buying an additional 1,295 shares in the last quarter.

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.